Yes, allergy risks associated with aspirin were recognized and considered early in its development and medical use.
Aspirin, synthesized by Felix Hoffmann at Bayer in 1897, was introduced commercially as Acetylsalicylic Acid in 1899. By 1902, reports documented severe reactions resembling anaphylaxis in sensitive patients, including skin rashes, asthma exacerbations, and fatal outcomes.[1][2] These were linked to aspirin's inhibition of cyclooxygenase-1 (COX-1), which disrupts arachidonic acid metabolism and triggers leukotriene release in aspirin-sensitive individuals, particularly those with asthma or nasal polyps (Samter's triad).[3]
How were these risks first identified?
Clinical observations emerged quickly post-launch. In 1902, Pringle reported a fatal asthma attack after aspirin ingestion.[1] By 1911, over 30 cases of "aspirin idiosyncrasy" were cataloged, including urticaria and angioedema.[2] Bayer's early labeling acknowledged "idiosyncrasy" risks, though warnings were minimal compared to modern standards.[4]
Why do some people have aspirin allergies?
True IgE-mediated allergies are rare (<1%); most reactions (up to 20% in asthmatics) are pseudo-allergic, driven by COX-1 blockade leading to overproduction of cysteinyl leukotrienes.[3][5] Genetic factors like ALOX5 variants increase susceptibility.[6]
How does FDA regulation address aspirin allergy today?
Since the 1962 Kefauver-Harris Amendments, aspirin labels mandate black-box warnings for risks in children (Reye's syndrome) and contraindications for allergy history.[7] The FDA requires hypersensitivity testing for at-risk patients, and desensitization protocols exist for those needing aspirin (e.g., cardiovascular cases).[8]
What alternatives exist for aspirin-allergic patients?
- Acetaminophen (Tylenol): First-line for mild pain/fever; no COX inhibition, lower allergy risk.[9]
- NSAIDs like ibuprofen: Often cross-reactive; avoid in sensitive patients.[5]
- COX-2 inhibitors (celecoxib): Safer for most, but test first.[10]
- Desensitization: Rapid oral protocols achieve 80-90% tolerance for short-term use.[8]
Have lawsuits arisen from overlooked allergy risks?
Yes, notable cases include a 1977 $1.2M verdict against Bayer for failing to warn of allergy in an asthmatic patient, highlighting evolving liability standards.[11] Modern claims focus on inadequate physician counseling rather than manufacturer fault.
[1]: PubMed - Early aspirin hypersensitivity reports
[2]: NEJM - Historical review of aspirin reactions
[3]: JACI - Mechanism of aspirin-exacerbated respiratory disease
[4]: Bayer Archives - Original aspirin labeling
[5]: AAAAI - Aspirin sensitivity guidelines
[6]: Nature Genetics - ALOX5 polymorphisms
[7]: FDA - Aspirin labeling requirements
[8]: UpToDate - Aspirin desensitization
[9]: Mayo Clinic - Pain reliever alternatives
[10]: Arthritis Foundation - COX-2 options
[11]: NY Times - 1977 Bayer lawsuit